01743nas a2200217   4500000000100000008004100001653003900042653002000081653001000101653002600111100001500137700001800152700001600170700001300186245010100199856009800300300001300398490000700411520109300418022001401511       2018                            d10aNeglected tropical diseases (NTDs)10aschistosomiasis10aDrugs10aSchistosomicide drugs1 aCalixto NM1 aDos Santos DB1 aBezerra JCB1 aSilva LA00aIn silico repositioning of approved drugs against Schistosoma mansoni energy metabolism targets.  uhttps://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0203340&type=printable  ae02033400 v133 a<p>Schistosomiasis is a neglected parasitosis caused by Schistosoma spp. Praziquantel is used for the chemoprophylaxis and treatment of this disease. Although this monotherapy is effective, the risk of resistance and its low efficiency against immature worms compromises its effectiveness. Therefore, it is necessary to develop new schistosomicide drugs. However, the development of new drugs is a long and expensive process. The repositioning of approved drugs has been proposed as a quick, cheap, and effective alternative to solve this problem. This study employs chemogenomic analysis with use of bioinformatics tools to search, identify, and analyze data on approved drugs with the potential to inhibit Schistosoma mansoni energy metabolism enzymes. The TDR Targets Database, Gene DB, Protein, DrugBank, Therapeutic Targets Database (TTD), Promiscuous, and PubMed databases were used. Fifty-nine target proteins were identified, of which 18 had one or more approved drugs. The results identified 20 potential drugs for schistosomiasis treatment; all approved for use in humans.</p>
  a1932-6203